Natural Biocon Standalone March 2023 Net Sales at Rs 0.86 crore, up 259.99% Y-o-Y
03-05-2023
Biocon Biologics facility gets EU GMP certification for Bevacizumab
Biotechnology major Biocon on Friday said the Bengaluru-based plant of Biocon Biologics has received EU GMP approval for a biosimilar product. Biocon Biologics' facility has received a certificate of GMP compliance for Bevacizumab from the representative European inspection authority -- Health Products Regulatory Authority (HPRA), Ireland. Bevacizumab is indicated for the treatment of various types of cancers and a specific eye disease. "This approval reflects Biocon Biologics compliance with the highest international regulatory standards and enables the company to continue addressing the needs of patients in the EU," a company spokesperson said in a statement. This (B3) facility, which is one of India's largest monoclonal antibodies (mAbs) manufacturing facilities, had received the EU GMP Certification for manufacturing biosimilar Trastuzumab last year, the spokesperson said. Biocon Biologics is a subsidiary of Biocon Ltd.28-04-2023
BIOCON LTD. - 532523 - Intimation Under Regulation 30 (6) Of SEBI Listing Obligations And Disclosure Requirements (LODR) Regulations, 2015
Meetings conducted with Institutional Investors/Research Analysts.28-04-2023
BIOCON LTD. - 532523 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyBIOCON LTD. 2CIN NO.L24234KA1978PLC003417 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 1070.00 4Highest Credit Rating during the previous FY AA+ 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)INDIA RATINGS AND RESEARCH PVT. LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. YES Name of the Company Secretary: Mayank Verma Designation: Company Secretary and Compliance Officer EmailId: [email protected] Name of the Chief Financial Officer: Indranil Sen Designation: Chief Financial Officer EmailId: [email protected] Date: 27/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.27-04-2023
BIOCON LTD. - 532523 - Board Meeting Outcome for Outcome Of The Board Meeting
The Board of Directors of Biocon Limited at its meeting held today, i.e. on Wednesday, April 26, 2023, has approved the transaction for issuance of Secured, Redeemable, NCDs aggregating upto Rs. 500 crores on private placement basis to ESOF III Investment Fund managed by Edelweiss Alternate Asset Advisors Limited (EAAA) and EAAA. The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%. The proceeds from the NCDs will be further invested by Biocon Limited as OCDs in BBL on similar terms as the NCDs. The Board of Directors of BBL has considered and approved the execution of the transaction documents for issuance of CCDs of BBL aggregating upto Rs. 300 crores to Investors. CCDs will convert to 1:1 BBL shares with a contingent coupon to guarantee minimum 12% IRR. The consummation of above transactions are subject to customary regulatory approvals and conditions precedent. The Board Meeting commenced at 8:45 pm and concluded at 9:20 pm.26-04-2023
Serum arm to double investment in Biocon unit
This is an addition to Serum's previous investment in November 2022, when it invested $150 million for a stake in the biosimilar subsidiary.25-04-2023
BIOCON LTD. - 532523 - Notification
Please find enclosed a notification titled 'Serum & Biocon Biologics Agree to Restructure Equity Investment'. The above information will also be available on the website of the Company at www.biocon.com.25-04-2023
Biocon to consider issuance of NCDs on private placement basis on April 26
Biocon Biologics Sunday said that it would hold a meeting of Board of Directors on April 26, 2023 to consider issuance of secured, redeemable, non-convertible debentures (NCDs) on private placement basis24-04-2023
BIOCON LTD. - 532523 - Board Meeting Intimation for Intimation Pursuant To Regulation 29(1)(D) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
BIOCON LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/04/2023 ,inter alia, to consider and approve Pursuant to Regulation 29(1)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, April 26, 2023, inter alia, to consider the issue of Secured, Redeemable, Non-Convertible Debentures on private placement basis, investment in securities to be issued by Biocon Biologics Limited and provision of guarantees/put options, amongst other matters. The above-mentioned information will also be available on website of the Company at www.biocon.com. Request you to take the above intimation on record.23-04-2023